Overview

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Acrotech Biopharma LLC
Spectrum Pharmaceuticals, Inc
Collaborators:
Beckloff Associates, Inc.
Clinipace LTD
Clinipace Worldwide
Kansas City Bioanalytical Laboratories
Treatments:
Melphalan